Patent: 9,744,234
✉ Email this page to a colleague
Summary for Patent: 9,744,234
Title: | Methods of treating ankylosing spondylitis using IL-17 antagonists |
Abstract: | The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., 1L-1 7 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof). |
Inventor(s): | Mpofu; Shephard (Oberwil, CH), Richards; Hanno (Therwil, CH), Thangavelu; Karthinathan (Geneva, CH), Machacek; Matthias (Allschwil, CH) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 13/877,585 |
Patent Claims: | see list of patent claims |
Details for Patent 9,744,234
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | 01/21/2015 | ⤷ Try a Trial | 2030-11-05 |
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | For Injection | 125504 | 01/21/2015 | ⤷ Try a Trial | 2030-11-05 |
Novartis Pharmaceuticals Corporation | COSENTYX | secukinumab | Injection | 125504 | 05/28/2021 | ⤷ Try a Trial | 2030-11-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |